ASCO GU 2023-Prostate Cancer

Phouc T. Tran, MD, PhDASCO GU Symposium 2023 | February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
View More
Alan H. Bryce, MDASCO GU Symposium 2023 | February 24, 2023
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice.
Noel Clarke, MBBS, FRCS, ChMASCO GU Symposium 2023 | February 24, 2023
Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3.
David Nanus, MDASCO GU Symposium 2023 | February 24, 2023
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
Neeraj Agarwal, MDASCO GU Symposium 2023 | February 24, 2023
Neeraj Agarwal, MD, highlights the significance of TALAPRO-2 in mCRPC and the data for rPFS with respect to HRR status.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A new study examined the relationship between pathogenic germline BRCA2 mutation and somatic change in circulating tumor DNA.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
Radical prostatectomy for patients with locally advanced, node-positive, and metastatic PC may be an effective option.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A cohort analysis found that PSMA PET at baseline, before pRT, or before sRT may predict from pelvic radiotherapy.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A new analysis demonstrates “excellent potential” for a radiomic-based diagnostic tool to identify PC recurrence risk.
Zachary BessetteASCO GU Symposium 2023 | October 12, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A comparative effectiveness study showed the optimal method of determining prostatic volume of prostate cancer.
Emily MenendezASCO GU Symposium 2023 | August 23, 2023
A study assessed the differences in OS and health care resource utilization by race in Medicaid-insured patients with mCSPC.
Emily MenendezASCO GU Symposium 2023 | February 16, 2023
Researchers used 14 prognostic genes to make a biopsy-based 6-gene signature to risk-stratify patients with early-stage PCa.
Emily MenendezASCO GU Symposium 2023 | February 16, 2023
A study reviewed the prognostic value of neuroendocrine differentiation in mCRPC patients receiving abiraterone or docetaxel.
Zachary BessetteASCO GU Symposium 2023 | February 8, 2023
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.
Advertisement
Advertisement